Publication | Open Access

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG

Cancer ImmunosurveillanceMedicineMelanomaImmunologyMetastatic MelanomaTherapeutic VaccineImmune Checkpoint InhibitorVersus VaccinationDc Study GroupImmunotherapyOncologyRadiation Oncology